This online educational activity is directed toward ophthalmologists and other healthcare professionals involved in treating patients with MGD-associated DED.
Dry eye disease (DED) is one of the most common ocular diseases encountered by eye care professionals, and meibomian gland dysfunction (MGD) is a frequent cause of DED. Historically, treatments for MGD have focused on alleviating symptoms using artificial tears or warming procedures with compression to melt and expel viscous meibum. Pharmacologic therapies comprise antibiotics and immunomodulators directed at inflammation, but no agents have yet been approved by the United States Food and Drug Administration specifically for MGD. Emerging agents may bring new mechanisms for MGD management.
The Ophthalmology Consultations™ is a video-based program in which two experts discuss the treatment and management of management of MGD-associated DED. In this activity the faculty focus on the current and emerging therapeutic strategies for the management of MGD-associated DED. This engaging format is designed to help clinicians identify best practices in the diagnosis and management of MGD-associated DED and to improve outcomes for their patients with this disease.
Upon completion of this activity, participants should be better able to: